Pyc Therapeutics Limited · ASX:PYC
Pyc Therapeutics — Phylogica — Investor Presentation (July 2006)
23 slides from Pyc Therapeutics's investor presentation, Jul 17, 2006
Slide 1: Phylogica Investor Presentation
PHYLOGICA Investor Presentation Perth, Australia 17 July 2006: Australian drug discovery company, Phylogica (ASX: PYC), will be presenting to brokers and advisors. The powerpoint presentation follows. For further information, please contact: Media Phylogica Daniella Goldberg Stewart Washer +61 2 923
Slide 2: Dr Stewart Washer, Chief Executive Officer
Dr Stewart Washer Chief Executive Officer July, 2006
Slide 3: Corporate Overview
ate Overview _ Major Shareholders _ Biotech Capital Ltd: 26.9% Institute for Child Research: 19.0% -Dr Paul Watt... 3.7% Share Price and Volume Past 6 months a1 EAE Pet Bai ty i a YLOGICA FOU BU TIBODIES
Slide 4: Recent Events
2nt Events h and Opsona Therapeutics : HYLOGICA OUD BU TIBI LES:
Slide 5: Why Invest in PYC?
estin PYC? opie, Technology and Market >. oin inflammatory diseases urns. and stroke kets with unmet needs gy (Phylomers®) value beyond antibodies, US$1 tbn drug rope and Australia/NZ HYLOGICA OUD BU TIBI LES:
Slide 6: Board and Management
Land Management f experience and expertise © ‘i) von Roy — Chairman — Chief Executive Officer and MD EO. and Board experience in - inology companies vard Universities HYLOGICA NOD BM TIB ODES
Slide 7: Board and Management
nd Management fexperience and expertise. — hief Operations Manager ience in the pharmaceutical and try ss development, IP. management and ar -. Director Business Deve mercial biotechnology and.mo nce : ry knowledge and expertise in ss management YLOGICA HO AW TIBODIES
Slide 8: Building Partnerships
ing Partnerships __ YLOGICA a AU TIBODIES
Slide 9: Business Model
s Model ealising value around our Phylomer® drugs at cal License) ilestone payments, royalties will be undertaken where a client rget validated - als - where a partner-wan veloped to. a unique dise: I co- -development deals i HYLOGICA DUD AMIR ODES
Slide 10: Drug Pipeline
ug Pipeline BURN TREATMENT ~~ Collaborators eek 6h—rltC< “® J&J Research ~~~ Garvan Institute “© Baker Institute IRRITABLE Bw. . ne ACWITE SYNDROME = faaiunan eases a HYLOGICA ies
Slide 11: Antibodies have revolutionised the treatment of cancer
‘side effects, cost effective, tionalised the treatment of cancer es “Pirinttearnmentiondhs SKtinwonpereictia Wipiteorserentecte: IYLOGICA Noe & TES
Slide 12: Mechanism of Action
anism of Action HO AW TIBODIES
Slide 13: Commercial Proposition
ial Proposition ond antibodies ct replacement ; S$11bn drug class) eneration uced costs) ntial (Patient Friendly) ck (More Profits) — an be used for disease targ bodies cannot penetrate cells YLOGICA OUD BU TIBI LES:
Slide 14: Events surrounding the initial stroke event
rrounding the initial event die ists to prevent this cell death and . Impairment of function (penumbra) Structural lesion Oe eS HYLOGICA DUD AMIR ODES Days & weeks
Slide 15: Stroke
7 Stroke completely prevented stroke and Alzheimer mode! al global brain damage model munogenicity and affinity was al DUD AMIR ODES
Slide 16: Burns
Burns leading cause of accidental lls surrounding the injury site r-to the damage following a - HYLOGICA NOD BM TIB ODES
Slide 17: Burns
Burns_ executed with Dr Fiona Wood fate PYC35B has demonstrated ic data positive g progressed i in deep bu undation ~ HYLOGICA DUD AMIR ODES
Slide 18: Rheumatoid Arthritis
A) is a chronic autoimmune und 1%. of the population expensive and not.very tments represent significant } current.therapies; - :d cost of goods llectual property royalty i y potential HYLOGICA HO AMT IBO DIES
Slide 19: Rheumatoid Arthritis
atoid Arthritis - ed A$2.3 million-of funding from rant for this project signed with the University of d leaders in RA research YLOGICA O ANTIBODIES
Slide 20: Development Portfolio
elopment Portfolio target HYLOGICA PO AU TIBOD IES
Slide 21: Biotech Comparators
jiotech Comparators. alue™ biotechnology companies in the biological drug discovery dge Antibody Technologies who - ody drug development and Astré ed US$1.3bn (total value) fo ce are Morphosis, Dyax aj earlier stage developme’ YLOGICA O ANTIBODIES
Slide 22: Summary
ul m ma ry y technology major advantages over other drugs ) ) treat unmet need markets: is treatment (PYC35B) and RA ugs can be developed from the logy: ; sed on early revenue and. with Pharma and biotech OUD BU TIBI LES:
Slide 23: Phylogica Limited
gica Limited eyond Antibodies HYLOGICA OUD BU TIBI LES: